Free Trial

AstraZeneca (AZN) Stock Price, News & Analysis

AstraZeneca logo
$64.12 +0.92 (+1.46%)
(As of 11/21/2024 ET)

About AstraZeneca Stock (NASDAQ:AZN)

Key Stats

Today's Range
$63.53
$64.15
50-Day Range
$63.20
$79.58
52-Week Range
$60.47
$87.68
Volume
6.68 million shs
Average Volume
5.32 million shs
Market Capitalization
$198.83 billion
P/E Ratio
30.68
Dividend Yield
1.53%
Price Target
$89.75
Consensus Rating
Moderate Buy

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
78th Percentile Overall Score

AZN MarketRank™: 

AstraZeneca scored higher than 78% of companies evaluated by MarketBeat, and ranked 224th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AstraZeneca has only been the subject of 3 research reports in the past 90 days.

  • Read more about AstraZeneca's stock forecast and price target.
  • Earnings Growth

    Earnings for AstraZeneca are expected to grow by 14.63% in the coming year, from $4.10 to $4.70 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 30.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.63.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 30.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.15.

  • Price to Earnings Growth Ratio

    AstraZeneca has a PEG Ratio of 1.17. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AstraZeneca has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AstraZeneca's valuation and earnings.
  • Percentage of Shares Shorted

    0.15% of the outstanding shares of AstraZeneca have been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently increased by 14.89%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    AstraZeneca pays a meaningful dividend of 1.54%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 46.89%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 20.85% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

  • Read more about AstraZeneca's dividend.
  • Percentage of Shares Shorted

    0.15% of the outstanding shares of AstraZeneca have been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently increased by 14.89%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    AstraZeneca has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 38 news articles for AstraZeneca this week, compared to 18 articles on an average week.
  • Search Interest

    37 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 208% compared to the previous 30 days.
  • MarketBeat Follows

    Only 18 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 20.35% of the stock of AstraZeneca is held by institutions.

  • Read more about AstraZeneca's insider trading history.
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Berenberg Bank Sticks to Their Buy Rating for AstraZeneca (AZN)
UBS upgrades AstraZeneca (AZN) to a Hold
Lunit announces collaboration with AstraZeneca to develop AI-powered tools
See More Headlines

AZN Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $67.35 at the beginning of the year. Since then, AZN shares have decreased by 4.8% and is now trading at $64.1250.
View the best growth stocks for 2024 here
.

AstraZeneca PLC (NASDAQ:AZN) posted its quarterly earnings data on Tuesday, November, 12th. The company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.03. The company's revenue for the quarter was up 18.0% compared to the same quarter last year.

AstraZeneca's stock split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

AstraZeneca subsidiaries include these companies: Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and others.

AstraZeneca's top institutional shareholders include Primecap Management Co. CA (1.35%), Wellington Management Group LLP (1.20%), FMR LLC (0.75%) and Sanders Capital LLC (0.48%).
View institutional ownership trends
.

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol-Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

Ex-Dividend for 9/9 Dividend
8/09/2024
Dividend Payable
9/09/2024
Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/13/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AZN
Employees
89,900
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$89.75
High Stock Price Target
$97.00
Low Stock Price Target
$82.00
Potential Upside/Downside
+40.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$5.96 billion
Pretax Margin
15.47%

Debt

Sales & Book Value

Annual Sales
$45.81 billion
Cash Flow
$5.39 per share
Book Value
$13.16 per share

Miscellaneous

Outstanding Shares
3,100,610,000
Free Float
N/A
Market Cap
$197.63 billion
Optionable
Optionable
Beta
0.47

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:AZN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners